Chemoproteomics market seen reaching $3.35 billion by 2030

By AI, Created 5:20 PM UTC, May 18, 2026, /AGP/ – The chemoproteomics market is projected to grow from $1.77 billion in 2025 to $3.36 billion by 2030 as drug discovery, proteomics research and personalized medicine demand accelerate. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Chemoproteomics is becoming more important in drug discovery, biomarker identification and proteomics research. - The market’s growth points to wider use of advanced analytical tools in pharmaceutical R&D and precision medicine. - The forecast suggests stronger demand for platforms that can map protein interactions and support targeted therapies.

What happened: - The chemoproteomics market is estimated at $1.77 billion in 2025 and $2.01 billion in 2026. - The market is projected to reach $3.36 billion by 2030. - The forecast implies a 13.7% compound annual growth rate from 2026 to 2030. - The Business Research Company released the forecast in its Chemoproteomics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035.

The details: - Historical growth has been driven by rising investment in proteomics research, expanding pharmaceutical R&D, wider adoption of advanced mass spectrometry, and increased drug discovery and biomarker identification activity. - The report cites growing academic and research institution activity as another support for the market. - The report says future growth will be fueled by AI in proteomics analyses, demand for high-throughput chemoproteomics platforms, personalized medicine, growth in contract research organizations, and multi-omics strategies. - The forecast period is expected to see more activity-based protein profiling, quantitative proteomics, structural proteomics, affinity-based protein profiling, label-free methods and isotope labeling technologies. - Chemoproteomics uses chemical probes to study protein interactions, protein function and protein modifications in complex biological systems. - The field helps identify drug targets, protein-ligand interactions and reactive sites across the proteome. - The report links chemoproteomics to drug discovery and biomarker research. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Personalized medicine is a major growth driver because it depends on identifying patient-specific biomarkers and protein-drug interactions. - The report says advances in genomic technologies and molecular diagnostics are making more customized treatments possible. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Those approvals included seven cancer drugs and three treatments for other conditions. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The regional outlook suggests the market’s strongest expansion may come from outside its current largest base.

What’s next: - The market will likely see more adoption of AI-enabled analysis and high-throughput workflows as chemoproteomics expands. - Growth in personalized medicine and contract research services is expected to keep driving demand through 2030. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company also points readers to related reports on gastric cancer therapy, over-the-counter drugs and aryl hydrocarbon receptor markets.

The bottom line: - Chemoproteomics is moving from a niche research tool toward a broader drug discovery and precision medicine market, with demand expected to nearly double by 2030.